Rapport Therapeutics, Inc. Common Stock
RAPPNASDAQHealthcare● Active
$36.68
+$0.58(+1.61%)
Market Cap$1.3B
P/E Ratio—
52W High$42.269
52W Low$10.505
Rapport Therapeutics, Inc. Common Stock (RAPP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RAPP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.42
Est. -$0.56 · +25.0%
Revenue
$0.02B
Est. $0.01B · +166.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
RAPP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.90 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.56 | -$0.42 | +25.0% | $0.02B | $0.01B | +166.7% |
| ▼ Q1 FY2026 | Mar 10, 2026 | -$0.65 | -$0.72 | -10.8% | — | — | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.77 | -$0.71 | +7.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.87 | -$0.75 | +13.8% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.77 | -$0.68 | +11.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 11, 2025 | -$0.62 | -$0.57 | +8.1% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.57 | -$0.50 | +12.3% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.90
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.42
EPS Est.
-$0.56
EPS Surpr.
+25.0%
Revenue
$0.02B
Q1 FY2026
Mar 10, 2026Miss
EPS Actual
-$0.72
EPS Est.
-$0.65
EPS Surpr.
-10.8%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.71
EPS Est.
-$0.77
EPS Surpr.
+7.8%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.75
EPS Est.
-$0.87
EPS Surpr.
+13.8%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.68
EPS Est.
-$0.77
EPS Surpr.
+11.7%
Revenue
—
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
-$0.57
EPS Est.
-$0.62
EPS Surpr.
+8.1%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.50
EPS Est.
-$0.57
EPS Surpr.
+12.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.16 | $-1.16 | $-1.16 | 1 |
| Q3 FY2027 | $-1.13 | $-1.13 | $-1.13 | 1 |
| Q2 FY2027 | $-1.10 | $-1.10 | $-1.10 | 1 |
| Q1 FY2027 | $-1.08 | $-1.08 | $-1.08 | 1 |
| Q4 FY2026 | $-1.04 | $-1.04 | $-1.04 | 1 |
| Q3 FY2026 | $-1.08 | $-0.97 | $-0.76 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +25.0% | $37.06 | $39.93 | +7.74% |
| ▼ Q1 FY2026 | Mar 10, 2026 | -10.8% | $30.54 | $29.63 | -2.98% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +7.8% | $26.17 | $25.36 | -3.10% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +13.8% | $14.61 | $15.41 | +5.48% |
| ▲ Q2 FY2025 | May 8, 2025 | +11.7% | $10.22 | $10.65 | +4.21% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +8.1% | $8.27 | $8.96 | +8.34% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +12.3% | $26.15 | $26.90 | +2.87% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -150.0% | $18.86 | $18.56 | -1.59% |
Q2 FY2026+7.74%
Report Date
May 7, 2026
EPS Beat/Miss
+25.0%
Price Before
$37.06
Price After
$39.93
Q1 FY2026-2.98%
Report Date
Mar 10, 2026
EPS Beat/Miss
-10.8%
Price Before
$30.54
Price After
$29.63
Q4 FY2025-3.10%
Report Date
Nov 6, 2025
EPS Beat/Miss
+7.8%
Price Before
$26.17
Price After
$25.36
Q3 FY2025+5.48%
Report Date
Aug 7, 2025
EPS Beat/Miss
+13.8%
Price Before
$14.61
Price After
$15.41
Q2 FY2025+4.21%
Report Date
May 8, 2025
EPS Beat/Miss
+11.7%
Price Before
$10.22
Price After
$10.65
Q1 FY2025+8.34%
Report Date
Mar 11, 2025
EPS Beat/Miss
+8.1%
Price Before
$8.27
Price After
$8.96
Q4 FY2024+2.87%
Report Date
Nov 7, 2024
EPS Beat/Miss
+12.3%
Price Before
$26.15
Price After
$26.90
Q3 FY2024-1.59%
Report Date
Aug 8, 2024
EPS Beat/Miss
-150.0%
Price Before
$18.86
Price After
$18.56
Avg Beat Reaction+4.26%
Avg Miss Reaction-2.29%
Beat Rate6 / 8 quarters
Largest Move+8.34% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RAPP ends December
Rapport Therapeutics, Inc. Common Stock (RAPP) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.42 — beating the analyst consensus of $-0.56 by +25.0%. The next RAPP earnings date is expected around September 1, 2026.
Each quarter, investors track RAPP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RAPP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RAPP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RAPP earnings · 5 questionsRapport Therapeutics, Inc. Common Stock's next earnings report is expected around September 1, 2026. RAPP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RAPP historically reports after market close (AMC).
RAPP earnings datewhen is RAPP earningsRAPP next earnings datewhen does RAPP report earningsRAPP earnings calendar
▸ Source: FMP · Rapport Therapeutics, Inc. Common Stock SEC filings · US GAAP · Rapport Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026